MKI67 and neoplasm: Therefore, when making the decision of adjuvant treatment, it is necessary not only to accurately evaluate the tumor’s biological behavior, but also to consider the level of immunohistochemistry such as Ki67 or according to the patients’ other clinicopathological indicators to reduce the risk of postoperative recrudescence and enhance prognosis (37).